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Introduction
Whooping cough (pertussis), a respiratory disease caused by 
Bordetella pertussis, accounts for more than 3,00,000 deaths annually 
worldwide [1,2] and its incidence has been rising [3]. B. pertussis is a 
non-invasive pathogen which localises mainly in the upper respiratory 
tract and produces a large array of potential virulence factors, many 
of which play significant roles in the pathogenesis of pertussis [1,4]. A 
killed whole cell pertussis vaccine, generally given in combination with 
diphtheria and tetanus toxoids, has been available in many countries 
for over 40 years. While its use seems to have controlled pertussis 
epidemics, concerns over the reactogenicity, ranging from high fever, 
persistent crying, pain and swelling at the site of injection [4,5] led 
to the development of the currently marketed acellular pertussis 
vaccines (DTaP) which is administered to infants in Australia at 2, 4, 
and 6 months with a booster at 4-6 years of age [5]. In other countries 
like the USA, children are also vaccinated at 12-18 months of age 
[4]. Children under the age of 2 months of age are highly susceptible 
to the complications of pertussis infection but are too young to be 
immunised. The concern that young adults (vaccinated during their 
childhood) with waning immunity against whooping cough may serve 
as a reservoir for the pathogen for infecting infants (and children), has 
stimulated interest in the development of an alternative vaccine which 
can also be used safely in the adult population [6]. 
It is generally accepted that the protective efficacy of the acellular 
vaccine is short–term, not long-term [7]. Furthermore, given the 
frequency of local reactions [5,8], particularly the reported extensive 
limb swelling [5] that occured in a children receiving 4th booster 
vaccinations with DTaP, may raise an alarm, albeit undue, in the 
community about the safety of this vaccine. The alternatives suggested 
have been to either to reduce the number of booster immunisation 
show ever this would lead to reduced levels of immunity, use vaccines 
with reduced antigen content as has been done by introduction of adult 
acellular pertussis vaccine formulations, dTpa, for use in adolescents 
(http://immunise.health.gov.au), or to find a replacement adjuvant, 
which, unlike alum, favours the induction of Th1 responses that has been 
proposed to be responsible for long-term protection against whooping 
cough [9]. Unfortunately, no such universally acceptable adjuvant for 
use with DTaP approved by the Food and Drugs Administration (FDA) 
is available, hence the continued use of the alum-based adjuvants in 
pertussis vaccine formulations. 
Comparison of the humoral and cellular immune responses of 
mice following vaccination with the killed whole cell pertussis vaccine 
(WCV:DTPw) versus the DTaP [10] has revealed that although the 
DTPw induced lower antibody titres to the pertussis toxin, filamentous 
haemagglutinin and pertactin, it was more effective in activating 
macrophages and more protective as judged in intracerebral challenge 
and bacterial lung clearance experiments than the DTaP [10]. These 
authors suggested that cell-mediated immunity might play a crucial role 
in eliminating bacteria that escape the humoral defence mechanisms. 
This suggestion is further supported by the fact that B. pertussis can 
survive within mammalian cells including macrophages [11,12]. It has 
also been suggested that circulating antibodies may play a role in toxin 
neutralisation and prevention of bacterial attachment to respiratory 
epithelial cells particularly in the early phase of infection [10]. There is 
now evidence that whole-cell pertussis priming in infancy may be more 
effective than DTaP priming on subsequent protection in childhood [13].
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Abstract
Bordetella pertussis, the aetiological agent of an acute upper respiratory tract disease of humans, “whooping 
cough”, can infect all age groups with adolescents and adults acting as major source of transmission of this pathogen 
to infants. This transmission is promoted by the fact that adolescents and adults do not exhibit the characteristic cough, 
the infection being either asymptomatic or manifested as a mild but persistent upper respiratory tract infection. It is 
established now that both antibodies and cell-mediated immune [CMI] responses are crucial for protection against 
whooping cough, the former being important in the early phase of the disease, with the latter being important for 
long-term protection. The protection offered by vaccination with the currently-marketed acellular pertussis vaccines 
is predominantly due to antibodies against vaccine antigens associated with a Th2-polarised immune response 
and has been found to be relatively short-term protection. There is an urgent need to develop alternative vaccines 
capable of inducing both protective antibody and CMI responses particularly given the resurgence of this vaccine-
preventable disease in infants and children worldwide. While current strategies are aimed at the development of 
recombinant vaccines using an adjuvant that may stimulate both arms of the immune response, no discovery of a 
cost-effective and non-toxic adjuvant to improve protection against pertussis has been reported thus far. This review 
details the oral presentation on alternative whooping cough vaccines and their future potential delivered at the 2nd 
World Conference on Vaccines and Vaccination organised by the OMICS Publishing Group. 
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The perceived fears of potential adverse reactions to whole 
cell pertussis vaccines, and the cost-ineffectiveness of DTaP 
formulationsfor socially or financially disadvantaged populations 
worldwide, investigations aimed at developing novel but affordable 
pertussis vaccines are essential and are constantly in progress in 
different relevant organisations. The 1st approach that is being tested 
is the development of biodegradable nanoparticle-encapsulated 
whooping cough vaccine. B. pertussis subunit antigens [PTxoid, FHA, 
PRN] administered intranasally or parenterally to mice following 
encapsulation in biodegradable micro- or nanoparticles was reported 
to induce CMI (Th1-polarised) or antibody (Th2-polarised) responses 
but the protection was no better than that induced by pertussis antigens 
administered in solution [14,15].
The 2nd approach has been the development of DNA vaccines for 
prevention of infection with B. pertussis has revealed that the arm of 
the immune response induced depended on not only the eukaryotic 
vector used for expression of the viruence antigens but also application 
of prime boost strategy invloving purified recombinant potential 
protective antigens or select cytokines. Li et al. [16] reported that use 
of prime boost strategy involving co-administration of Granulocyte 
Macrophage Colony Stimulating Factor [GMCSF]. Kamachi et al. [17] 
reported protection against B. pertussis challenge in mice vaccinated 
using a gene gun with a DNA vaccine comprising the full S1 subunit 
of pertussis toxin expressed in pcDNA 3.1 vector. However, because 
of the potential logistical difficulties associated with the method of 
immunisation, Fry et al. [18] reported that immunisation of mice by 
the intramuscular route with a DNA vaccine constructed using the 
pcDNA 3.1 vector expressing pertussis toxoid induced a significant cell-
mediated immune response but only little antibody response. Although 
mice were protected upon challenge with the virulent parent, the rate 
of bacterial clearance was better in DTaP- vaccinated mice. Further 
studies revealed that booster vaccination of DNA vaccine-immunised 
mice with purified recombinant pertussis toxoid produced significantly 
higher level of antibodies and cell-mediated immunity than vaccination 
with the DTaP vaccine (Fry, Chen, Daggard and Mukkur, unpublished), 
rendering such a vaccine unaffordable for majority of the population 
potentially because of the potential increase in manufacturing costs and 
concerns regarding safety of DNA vaccines. 
Another promising option is the development of live attenuated 
whooping cough vaccine delivered by the nasal route, so as to mimic 
the natural route of infection, potentially leading to induction of long 
lasting immunity. Roberts et al. [19] developed an aromatic-dependent 
mutant (aroA) of B. pertussis, but found to the vaccine strain to persist 
in the lungs of mice for only a short period of time (4 days at reasonable 
numbers) thus casting doubt on its ability to stimulate effective cell-
mediated immunity (CMI) considered to be essential for long-term 
protection against whooping cough. This result was unexpected 
given previous reports regarding the success of the aroA mutant of 
Salmonella species [20,21]. as a successful vaccine. On the other hand, 
the aroA mutants of Shigella species were found to be poorer vaccines 
than the aroD deletion mutants of the same species [22,23]. Mielcarek 
et al. [24] developed B. pertussis vaccine candidate [BPZE1] in which 
PT was attenuated by genetic detoxification, dermatonecrotoxin (dnt) 
was deleted and ampG gene replaced with the orthologous E. coli ampG 
gene, with the aim of modulating the activity of tracheal cytotoxinand 
reported to be immunogenic in young [3 week-old] mice and adult 
mice. We provide a review of the immunobiological properties of 
aromatic-deficient [aroQ] B. pertussis [hereafter referred to as aroQBP] 
developed in our laboratory, including humoral and cellular immune 
response pre- and post-challenge with the aroQBP vaccine candidate 
[25] and its future potential.
Methods and Materials
Method of construction of the aroQBP vaccine candidate, 
immunisation, measurement of the antibody isotype and cell-mediated 
immune responses, using IL-2 and IFN-γ as indirect indicators, and 
protection against challenge with virulent B. pertussis have been 
described in detail elsewhere [25].    
Results
The aroQ B. pertussis mutant (aroQBP) vaccine candidate [25] was 
found to survive longer in mice than the aroA B. pertussis mutant [19] 
and found to be detectable until days 10-12 post-immunisation (Figure 1). 
Immunisation of mice with the aroQBP vaccine resulted in the 
induction of anti-filamentous haemagglutinin (FHA), anti-pertussis 
toxin (PT) and anti- B. pertussis killed whole cells (BPWC) antibodies 
of the IgG isotypes, IgG1 and IgG2a (Figures 2-7) in the serum [24] 
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Figure 1: Persistence of aroQ B. pertussis [aroQBP] in the lungs of vaccinated 
mice (data from reference [25] re-plotted for enhanced clarity).
Figure 2: Anti-FHA IgG1 response of mice vaccinated with a single dose 
of aroQBP versus 0.1 mL of a single standard human dose pre- and post-
challenge with virulent B. pertussis (data from reference [25] re-plotted for 
enhanced clarity).
Citation: Mukkur T, Richmond P (2013) Alternative Whooping Cough Vaccines: A Minireview. J Vaccines Vaccin 4: 175. doi:10.4172/2157-
7560.1000175
Page 3 of 5
Volume 4 • Issue 1 • 1000175
J Vaccines Vaccin
ISSN:2157-7560 JVV an open access journal
and/or lung homogentes. In contrast, neither IgG2a nor CMI-indicator 
cytokines were detectable. 
While IgG1 and IgG2a were produced in respiratory secretions 
[lung homogenates] of mice immunised with the aroQBP vaccine 
(Table 1), only the IgG1 isotype was detectable in the lung homogenates 
of mice vaccinated with DTaP. 
In addition, cell-mediated immunity (CMI) against B. pertussis, 
as judged by production of IL-2 and IFN-γ, was induced only in mice 
that were immunized with the live aroQBP vaccine candidate by the 
intranasal route (Table 2).
Mice immunised with a single dose of the aroQBP vaccine were 
protected against challenge infection with the virulent parent up to the 
dose of 4.2×1010 colony forming units [CFUs] whereas protection in 
mice with one dose of the DTaP were only partially protected when 
challenged with a dose of the same dose (Table 3).
Discussion
In order to ensure maintenance of herd immunity against whooping 
cough, a minimum of five vaccinations with either a whole cell pertussis 
Figure 3: Anti-FHA IgG2a response of mice vaccinated with a single dose 
of aroQBP versus 0.1 ml of a single standard human dose pre- and post-
challenge with virulent B. pertussis (data from reference [25] re-plotted for 
enhanced clarity).
Day post immunisation ot post-challenge
Figure 4: Anti-PT IgG1 response of mice vaccinated with a single dose 
of aroQBP versus 0.1 ml of a single standard human dose pre- and post-
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Figure 6: Anti-BPWC IgG1 response of mice vaccinated with a single dose 
of aroQBP versus 0.1 mL of a single standard human dose pre- and post-























Figure 7: Anti-BPWC IgG2a response of mice vaccinated with a single dose 
of aroQBP versus 0.1 ml of a single standard human dose pre- and post-
challenge with virulent B. pertussis (data from reference [25] re-plotted for 
enhanced clarity).
Figure 5: Anti-PT IgG2a response of mice vaccinated with a single dose 
of aroQBP versus 0.1 ml of a single standard human dose pre- and post-
challenge with virulent B. pertussis (data from reference [25] re-plotted for 
enhanced clarity).
Vaccine IgG1 IgG2a
aroQ B. pertussis 50 80
DTaP 220 0
Values shown represent reciprocal endpoint titre
Table 1: IgG1 and IgG2a antibody titres against whole-cell B. pertussis [BPWC] 
Tohama I of pooled lung homogenates of mice vaccinated with a single dose of 
aroQ B. pertussis or 3 doses of DTaP vaccine. 
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vaccine (DTwP) or acellular pertussis vaccine (DTaP), depending upon 
the country, are required. In Australia, vaccination is recommended at 
2, 4 and 6 months of age, 4 years and 15-17 years, followed by a single 
booster dose of reduced antigen content vaccine (dTpa) for all adults 
planning a pregnancy, for both parents, grand parents and carers as soon 
as possible after delivery of the infant. The major problems asociated 
with the use of these vaccines is the relatively short duration of immunity 
imparted by the DTaP due potentially to predominant induction of Th2 
polarised immune response and lack of CMI induction after primary 
immunisation with the DTaP vaccine as demonstrated in studies using 
the pertussis mouse model [1,26] and the perceived fear of serious side 
reactions despite the fact that the encephalopathy/encephalitis, febrile 
seizures/provocation of convulsions, and sudden deaths have been 
reported to be significantly lower with acellular pertussis vaccination 
than with whole cell pertussis vaccination [27].
The live attentuated vaccines, on the other hand, may require 
one or 2 booster vaccination at best to provide potential longer term 
protection as already reported for a different live attenuated vaccine 
candidate, BPZE1 [24], using the pertussis mouse model. In the latter 
vaccine candidate, the pertussis toxin gene has been modified to render 
the pertussis toxin non-toxic, dermonecrotoxin (DNT) gene deleted 
and the ampG gene replaced with an E. coli counterpart with the aim 
of modulating/reducing the potential toxicity of tracheal cytotoxin 
(TCT). More recently, a phase trial in adult humans was carried out 
with this vaccine candidate, results of which have not been published 
as yet. It will be interesting to determine the immunological properties 
of the BPZE1 vaccine candidate following deletion of an essential gene 
such as the aroQ gene. Regardless of the type of attenuated vaccine 
candidate however, it is important to determine the level of protection 
afforded by these vaccine candidates against challenge with the clinical 
isolates showing polymorphisms in different virulence antigens [28]. It 
is therefore desirable to ensure that all live attenuated vaccine strains 
including BPZE1 and aroQBP vaccine candidates are non-reverting 
completely non-toxic and can also impart protection against the newly 
emerging B. pertussis isolates. 
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